NM_000329.3(RPE65):c.311G>A (p.Gly104Asp) is a missense variant resulting in replacement of glycine by aspartic acid at amino acid 104. Another missense variant in the same codon, NM_000329.3(RPE65):c.310G>A (p.Gly104Ser), has been reported in relation to RPE65-related recessive retinopathy (PMID: 26667666), however, the SpliceAI score of 0.01 for the NM_000329.3(RPE65):c.311G>A (p.Gly104Asp) variant and the score of 0.29 for the NM_000329.3(RPE65):c.310G>A (p.Gly104Ser) comparison variant were not within 10% of one another, so PM5 is not met. This variant is present in gnomAD v.4.1.0 at a GrpMax allele frequency of 0.000000847, with 1 allele / 1,180,012 total alleles in the European (non-Finnish) population, which is lower than the ClinGen LCA / eoRD VCEP PM2_Supporting threshold of <0.0002 (PM2_Supporting). This variant has been reported in at least 2 probands with early-onset severe retinal dystrophy who were compound heterozygous with either the NM_000329.3(RPE65):c.118G>A (p.Gly40Ser) variant suspected in trans (0.5 points, PMID: 19117922) or the NM_000329.3(RPE65):c.272G>A (p.Arg91Gln) variant confirmed in trans (1 point, PMID: 34830511, PMID: 25356976), both of which was previously classified pathogenic by the ClinGen LCA / eoRD VCEP (1.5 total points, PM3). At least one proband harboring this variant exhibits a phenotype including diagnosis of early onset severe retinal dystrophy (0.5 pts) with onset of night blindness (0.5 pts) at age 3 years (1 pt), reduced central visual acuity (1 pt), and genotyping by a targeted exome sequencing panel of 188 known inherited retinal degeneration genes (2 pts), which together are specific for RPE65-related recessive retinopathy (total 5 points, PMID: 34830511, PP4). The computational predictor REVEL gives a score of 0.962, which is above the ClinGen LCA / eoRD VCEP threshold of ≥0.773 and predicts a damaging effect on RPE65 function (PP3_Moderate). The splicing impact predictor SpliceAI gives a score of 0.01, which is below the ClinGen LCA / eoRD VCEP recommended threshold of ≥0.2 and does not strongly predict an impact on splicing. In summary, this variant meets the criteria to be classified as likely pathogenic for RPE65-related recessive retinopathy based on the ACMG/AMP criteria applied, as specified by the ClinGen LCA/eoRD VCEP: PM2_Supporting, PM3, PP3_Moderate, and PP4. (VCEP specifications version 1.0.0; date of approval 09/21/2023).